GeneOne signs licensing agreement for RNA development

By Maggie Lynch

- Last updated on GMT

(Image: Getty/kasinv)
(Image: Getty/kasinv)

Related tags Rna License Developmental biology mRNA Good manufacturing practice

VGXI, a subsidiary of GeneOne, signed a licensing agreement with Houston Methodist Research Institute to produce RNA one of the most valued clinical ingredients.

Houston Methodist Research Institute is home to RNAcore, a RNA synthesis division led by professor and Chairman John Cooke. RNAcore generates RNA constructs including messenger RNA (mRNA), modified mRNA (mmRNA), microRNA cassettes, and noncoding RNA.

Per the licensing agreement, VGXI will use the design capabilities of the research institute to further develop RNA vaccines and therapies. A spokesperson from VGXI told us that the company has seen an increasing number of requests from clients for RNA manufacturing services, which served as a driver of the deal.

“RNA-based components are especially important for novel gene editing technologies, which are rapidly advancing toward the clinic,”​ the spokesperson further explained.

VGXI already has existing DNA services but the agreement will complement its current services.

“This [licensing agreement] will allow VGXI to support both DNA and RNA needs of our customers. In addition, high quality DNA is a necessary starting material for production of these kinds of RNA products, therefore the RNA services will be an ideal complement to VGXI’s existing capabilities and expertise in DNA manufacturing,”​ said the spokesperson.

RNA-based therapies are estimated to reach a market value of $1.2b by 2020​.

The RNA production will take place at VGXI’s facility. In preparation for this agreement, VGXI has made headway on expanding its facility in Woodlands, Texas. The expansion includes purpose-built good manufacturing process (GMP) production areas for RNA synthesis.

Related topics Preclinical Research Preclinical

Related news

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us

Products

View more

Webinars